Fludarabine
Histiocytosis
New York Medical CollegeSmall moleculePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Histiocytosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide New York Medical College | Phase 2 | B |
Thiotepa New York Medical College | Phase 2 | B |
Evomela New York Medical College | Phase 2 | B |
TACROLIMUS New York Medical College | Phase 2 | B |
Busulphan New York Medical College | Phase 2 | B |
View all 17 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →